Welcome to Neuren
A novel and dynamic biopharmaceutical company developing human therapies for neuroprotection and metabolic related disorders.
Recent announcements19 November 2013
Investor presentation, 19 November 2013
30 October 2013
Neuren receives orphan drug designation from the FDA for NNZ-2566 in Fragile X Syndrome
22 October 2013
Neuren completes new share placement of $21.5 million to accelerate execution of strategy